AstraZeneca to halt Cefotan sales
Executive Summary
AstraZeneca will discontinue sales of the injectable antibiotic Cefotan after current inventory is depleted in March 2006. Bulk active ingredient supplier Astellas (formerly Yamanouchi) has stopped production of cefotetan, as has sterile end product manufacturer GlaxoSmithKline, AstraZeneca says. The company began notifying hospitals and wholesaler customers two years ago about the pending inventory depletion and potential therapeutic alternatives, including Merck's Mefoxin (cefoxitin). Cefotan global net sales in 2004 were $39.6 mil., with most of those in the U.S, AstraZeneca notes...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.